Long-term effects of glibenclamide and nateglinide upon pancreatic islet function in normal and diabetic rats

被引:18
作者
Laghmich, A [1 ]
Ladrière, L [1 ]
Malaisse-Lagae, F [1 ]
Malaisse, WJ [1 ]
机构
[1] Free Univ Brussels, Expt Med Lab, B-1070 Brussels, Belgium
关键词
glibenclamide; nateglinide; pancreatic islet; insulin secretion;
D O I
10.1006/phrs.1999.0551
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Both control and hereditarily diabetic (Goto-Kakizaki) rats were administered twice daily for 7 days with an oral solution of carboxymethylcellulose containing, when required, glibenclamide (1.0 mu g g(-1) body wt.) or nateglinide (50.0 mu g g(-1) body wt.). The increase in plasma D-glucose concentration and decrease in insulinogenic index caused by the bleeding and handling of the rats prior to sacrifice was more pronounced in the hyperglycaemic and hyperinsulinemic diabetic rats than in the control animals. Eighteen hours after the last oral loading, a sizeable fall in plasma D-glucose concentration and increase in plasma insulin concentration was only observed in the glibenclamide-treated control rats, indicating a more prolonged biological effect of the hypoglycaemic sulphonylurea, as compared to the meglitinide analog. This coincided with the fact that the insulin content of the islets, their secretory response to a high concentration of D-glucose and their basal biosynthetic activity were more severely affected in glibenclamide than nateglinide-treated animals, especially in the control rats. It is proposed, therefore, that the meglitinide analog, considered as a new insulinotropic tool for the treatment of non-insulin-dependent diabetic subjects, may offer the far-from-negligible advantage of minimising the risk of a sustained decrease in both islet insulin content and glycaemia. (C) 1999 Academic Press.
引用
收藏
页码:475 / 482
页数:8
相关论文
共 16 条
[1]  
Bakkali-Nadi A, 1994, Diabetes Res, V27, P81
[2]  
Bergmeyer HU., 1974, METHOD ENZYMAT AN, P1205
[3]  
Jijakli H, 1997, MED SCI RES, V25, P813
[4]   Dynamics of the cationic and secretory responses to A-4166 in perifused pancreatic islets [J].
Jijakli, H ;
Ulusoy, S ;
Malaisse, WJ .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1997, 11 (04) :300-304
[5]   Pancreatic islet responsiveness to D-glucose after repeated administration of repaglinide [J].
Laghmich, A ;
Ladrière, L ;
Malaisse-Lagae, F ;
Malaisse, WJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 348 (2-3) :265-270
[6]   Stimulation of insulin and somatostatin release by two meglitinide analogs [J].
Leclercq-Meyer, V ;
Ladrière, L ;
Fuhlendorff, J ;
Malaisse, WJ .
ENDOCRINE, 1997, 7 (03) :311-317
[7]   MULTIPLE EFFECTS OF LEUCINE ON GLUCAGON, INSULIN, AND SOMATOSTATIN SECRETION FROM THE PERFUSED RAT PANCREAS [J].
LECLERCQMEYER, V ;
MARCHAND, J ;
WOUSSENCOLLE, MC ;
GIROIX, MH ;
MALAISSE, WJ .
ENDOCRINOLOGY, 1985, 116 (03) :1168-1174
[8]   Effect of N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine on nutrient catabolism in rat pancreatic islets [J].
Malaisse, WJ ;
Sener, A .
GENERAL PHARMACOLOGY, 1998, 31 (03) :451-454
[9]   STIMULATION OF INSULIN RELEASE BY NON-SULFONYLUREA HYPOGLYCEMIC AGENTS - THE MEGLITINIDE FAMILY [J].
MALAISSE, WJ .
HORMONE AND METABOLIC RESEARCH, 1995, 27 (06) :263-266
[10]   Insulinotropic action of meglitinide analogues: Modulation by an activator of ATP-sensitive K+ channels and high extracellular K+ concentrations [J].
Malaisse, WJ .
PHARMACOLOGICAL RESEARCH, 1995, 32 (03) :111-114